Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2059)	5/27/2003 9:24:03 AM
From: tuck	Read Replies (1) \| Respond to of 2243

Pope? >>8:23AM OXiGENE reports positive study results (OXGN) 2.80: Announces that a study published today in Anticancer Research highlights significant potency of anti-tumor compound. Also discloses that co and Cancer Research UK are collaborating on the final pre-clinical development of one of OXiGENE's most advanced vascular targeting agents, OXi4503. Under an agreement between the parties, Cancer Research UK will complete pre-clinical studies on OXi4503, then plan to move the compound into Phase I human clinical trials. << edit: maybe another: >>7:09AM Cell Therapeutics announces positive trial data (CTIC) 11.96: Announces that Trisenox has produced consistently high response rates in multiple myeloma patients who failed not only chemotherapy but also investigational compounds. Co says Trisenox is safe and well tolerated. In general, drug-related adverse were manageable and resolved after completion of therapy. << From Briefing.com Cheers, Tuck